Teva Completes $40B Purchase Of Allergan

August 4, 2016 | Israeli pharmaceutical giant Teva Pharmaceutical completed its $40 billion acquisition of the generics arm of rival Allergan on Tuesday, a move Teva hailed as confirmation of its intention to become one of the world’s largest drugmakers. The $40 billion deal, the largest in Israeli history, was agreed last year but finally confirmed on Tuesday. Allergan Generics was the third largest in the same market by sales, and the acquisition gives Teva a large market lead and catapults it into the top 10 pharmaceutical firms globally, according to the company’s figures.